Dear AuntMinnie member,
Over 75% of AI medical devices cleared or approved by the U.S. Food and Drug Administration (FDA) are used in radiology, but only 0.3% of these tools were tested for their impact on patient outcomes, according to our most highly viewed story of the week. Click here for all of the details.
Meanwhile, Episode 15 of our Ultrasound MinnieCast features a discussion on the promise of wearable ultrasound. You can access that episode here or by checking out the AuntMinnie Podcast Network.
In other news attracting attention on AuntMinnie last week, an AI software application that automatically drafts dual-energy x-ray absorptiometry (DEXA) reports led to significantly lower report creation and turnaround times. Another study found that flight attendants and airline pilots in the U.S. have the highest rates of radiation-related cancer mortality.
And routine CT scans used to plan radiotherapy for breast cancer can also yield an additional benefit: coronary artery calcium assessment to opportunistically screen for risk of heart disease, according to recent research.
We’re entering the final week of the nominations period of the Minnies, our annual awards program recognizing excellence in radiology. If you haven’t submitted your nominations yet, please do so here by August 31.
Please see below for our other top stories of the week.
Erik L. Ridley
Editor in Chief
AuntMinnie.com
1. Most FDA-cleared AI medical devices not tested on patient outcomes
2. Ultrasound MinnieCast, Episode 15: Wearable ultrasound making strides
3. AI system cuts DEXA turnaround time, improves reports
4. Radiation-related cancer mortality higher for U.S. flight crew
5. CT for breast radiotherapy detects ischemic heart disease risk
6. AI fracture detection device validated across three European hospitals
7. Thermal ablation achieves long-term survival in kidney cancer
8. PET/CT outperforms MRI after focal therapy for prostate cancer
9. MWA have long-term benefits for renal cell cancer patients
10. AI framework could improve MRI quality control in prostate cancer